As the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) expands, so too does our knowledge of just what all these medications can do. GLP-1RAs have now been shown to reduce consumption of alcohol and drugs, even treating addictions to gambling and sex, but these medications can also potentially lead to rare but fatal complications of...
As the onslaught of anti-obesity drugs hit the market in recent years, more research is being released about their potential side effects as well as their benefits. Endocrine News investigates two of these studies to gain more insight to how these “miracle drugs” could affect cardiac health. Two studies published in late 2025 examined cardiovascular...
In the United States, American Heart Month is observed in February to raise awareness about cardiovascular disease, the leading cause of death worldwide. To a similar end, Endocrine News focuses on a few recent journal studies that take a closer look at the impacts of incretin-based therapies in the setting of obesity and impaired cardiovascular...
The “black box” warning on the popular diabetes and weight loss drug semaglutide may be shifting from a cautionary black to a reassuring grey. A landmark study published in The Journal of Clinical Endocrinology & Metabolism reveals that semaglutide does not promote thyroid cancer; instead, it may suppress tumor growth by “reprogramming” the immune system...
Eli Lilly’s “Ozempic-in-a-pill” candidate just cleared its most significant clinical hurdle to date. The pharmaceutical giant announced that its experimental once-daily pill, orforglipron, met all primary and secondary endpoints in two pivotal Phase 3 trials: ACHIEVE-2 and ACHIEVE-5. Data indicate that this oral treatment provides superior glycemic control compared to both a standard SGLT-2 inhibitor...
A new year brings a new therapeutic milestone for weight management: Following its recent U.S. Food and Drug Administration approval, the 25 mg oral semaglutide tablet (brand name: Wegovy), a once-daily pill became available in the United States in early January 2026 for chronic weight management and for reducing the risk of major adverse cardiovascular...
A new study led by Mayo Clinic found that postmenopausal women receiving menopausal hormone therapy lost 35% more weight while taking tirzepatide. The findings, published in The Lancet Obstetrics, Gynaecology, & Women’s Health, could expand treatment possibilities for millions of women struggling with obesity and obesity-related diseases after menopause. Menopause can accelerate age-related weight gain and increase the likelihood of...
For the eleventh year running, Endocrine News talks to editors from Endocrine Society publications to unearth the most impressive breakthroughs in endocrine science and research for 2025. From GLP-1s, adrenal treatments, and acromegaly breakthroughs to obesity, diabetes, and cutting-edge research in reproductive medicine, 2025 was a banner year for endocrine research and researchers! For more...
As the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) expands, so too does our knowledge of just what all these medications can do. GLP-1RAs have now been shown to reduce consumption of alcohol and drugs, even treating addictions to gambling and sex, but these medications can also potentially lead to rare but fatal complications of...
For the eleventh year running, Endocrine News talks to editors from Endocrine Society publications to unearth the most impressive breakthroughs in endocrine science and research for 2025. From GLP-1s, adrenal treatments, and acromegaly breakthroughs to obesity, diabetes, and cutting-edge research in reproductive medicine, 2025 was a banner year for endocrine research and researchers! For more...
